A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) GS-US-384-1944

Grants and Contracts Details

StatusFinished
Effective start/end date8/1/178/31/18

Funding

  • Gilead Sciences Inc: $24,950.00